BiotechTube

Apitegromab + Placebo + Tirzepatide

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight and Obesity

Conditions

Overweight and Obesity

Trial Timeline

May 21, 2024 → Jun 17, 2025

NCT ID
NCT06445075

About Apitegromab + Placebo + Tirzepatide

Apitegromab + Placebo + Tirzepatide is a phase 2 stage product being developed by Scholar Rock Holding for Overweight and Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT06445075. Target conditions include Overweight and Obesity.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06445075Phase 2Completed

Competing Products

20 competing products in Overweight and Obesity

See all competitors
ProductCompanyStageHype Score
TERN-601Terns PharmaceuticalsPhase 2
49
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
33
LY3305677 + PlaceboEli LillyPhase 1
33
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
33
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
33
Tirzepatide + AcetaminophenEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
LY3437943 + PlaceboEli LillyPhase 1
33
LY3502970 + PlaceboEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
Eloralintide and Tirzepatide + EloralintideEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
LY3541105 + PlaceboEli LillyPhase 1
33
Retatrutide + PlaceboEli LillyPhase 2
52
LY4167586 + Placebo + LY4167586Eli LillyPhase 1
33
AZD9550 + AZD6234 + Placebo comparatorAstraZenecaPhase 2
52

Other Products from Scholar Rock Holding

Apitegromab + PlaceboPhase 3
74
ApitegromabPhase 3
74
Apitegromab + PlaceboPhase 2
49
SRK-015Phase 2
49
Apitegromab + Nusinersen + RisdiplamPhase 2
49